Basel, November 21, 2016 – Novartis today appear it has acquired Selexys Pharmaceuticals Corporation, a aggregation specializing in development of assay in assertive hematologic and anarchic disorders. Novartis acclimatized its appropriate to access Selexys afterward cancellation of after-effects of the SUSTAIN study, a Phase II balloon evaluating the use of SelG1, an anti-P-selectin antibody, in the abridgement of vaso-occlusive affliction crises in patients with sickle corpuscle ache (SCD). After-effects from the abstraction will be presented during the Plenary Scientific Session at the 58thAmerican Society of Hematology (ASH) Annual Meeting on December 4, 2016, in San Diego, California.
“Sickle corpuscle ache affects millions of bodies about the apple and there are bound therapies accessible for assay of vaso-occlusive affliction crises, a absolute accepted aggravation of the disease,” said Bruno Strigini, CEO of Novartis Oncology. “With this acquisition, Novartis is able to advantage its administration in hematology assay to beforehand development of a abeyant new assay advantage for patients active with this debilitating condition.”
SCD is a ancestral claret ataxia characterized by sickle-shaped red claret cells. It is a life-long ache with abounding forms that can ambit in analytic severity from asymptomatic to life-threatening. Vaso-occlusive crises, or affliction crises, are the above acumen for bloom affliction encounters in SCD and action episodically back sickle-shaped red claret beef block claret breeze through claret vessels.,
“We would like to extend our acknowledgment to all of the committed patients, physicians and nurses who alternate in the SUSTAIN abstraction of SelG1 in sickle corpuscle disease,” said Dr. Scott Rollins, above President and Chief Executive Officer of Selexys Pharmaceuticals. “Further, the accretion of Selexys by Novartis represents an important footfall in the connected development of SelG1, a novel, abeyant first-in-class assay for patients with this underserved life-threatening disease.”
Novartis acquired the absolute appropriate to access Selexys and SelG1 in 2012. Prior to the acquisition, Selexys Pharmaceutical Corporation was a a captivated biopharmaceutical aggregation headquartered in Oklahoma City, Oklahoma. Agreement of the accord could absolute up to $665 actor in upfront, accretion and anniversary payments.
DisclaimerThe above absolution contains advanced statements that can be articular by words such as “will,” “pipeline,” “commitment,” “potential,” “important step,” “continued development,” or agnate terms, or by accurate or adumbrated discussions apropos abeyant benefits, synergies or opportunities as a aftereffect of the accretion of Selexys Pharmaceuticals Corporation and SelG1, abeyant business approvals for SelG1 and the added artefact candidates in the Novartis hematology pipeline, or apropos abeyant approaching revenues from SelG1 and such added artefact candidates. You should not abode disproportionate assurance on these statements. Such advanced statements are based on the accepted behavior and expectations of administration apropos approaching events, and are accountable to cogent accepted and alien risks and uncertainties. Should one or added of these risks or uncertainties materialize, or should basal assumptions prove incorrect, absolute after-effects may alter materially from those set alternating in the advanced statements. There can be no agreement that Novartis will be able to apprehend any or all of the abeyant benefits, synergies or opportunities as a aftereffect of the accretion of Selexys Pharmaceuticals Corporation and SelG1. Neither can there be any agreement that SelG1 or the added artefact candidates in the Novartis hematology activity will be submitted or accustomed for auction in any market, or at any accurate time. Nor can there be any agreement that SelG1 or the added artefact candidates in the Novartis hematology activity will be commercially acknowledged in the future. In particular, management’s expectations apropos the accretion of Selexys Pharmaceuticals Corporation and SelG1, and the added artefact candidates in the Novartis hematology portfolio could be afflicted by, amid added things, the achievability that the abeyant benefits, synergies or opportunities accepted from the accretion may not be accomplished or may booty best to apprehend than expected; the uncertainties inherent in assay and development, including abrupt analytic balloon after-effects and added assay of absolute analytic data; abrupt authoritative accomplishments or delays or government adjustment generally; the company’s adeptness to access or advance proprietary bookish acreage protection; accepted bread-and-er and industry conditions; all-around trends against bloom affliction amount containment, including advancing appraisement pressures; abrupt safety, affection or accomplishment issues, and added risks and factors referred to in Novartis AG’s accepted Form 20-F on book with the US Securities and Exchange Commission. Novartis is accouterment the advice in this columnist absolution as of this date and does not undertake any obligation to amend any advanced statements independent in this columnist absolution as a aftereffect of new information, approaching contest or otherwise.
About NovartisNovartis provides avant-garde healthcare solutions that abode the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a adapted portfolio to best accommodated these needs: avant-garde medicines, eye affliction and cost-saving all-encompassing pharmaceuticals. Novartis is the alone all-around aggregation with arch positions in these areas. In 2015, the Group accomplished net sales of USD 49.4 billion, while R&D throughout the Group amounted to about USD 8.9 billion (USD 8.7 billion excluding crime and acquittal charges). Novartis Group companies apply about 118,000 full-time-equivalent associates. Novartis articles are accessible in added than 180 countries about the world. For added information, amuse appointment http://www.novartis.com.
Novartis is on Twitter. Sign up to chase @Novartis at http://twitter.com/novartis and @NovartisCancer at http://twitter.com/novartiscancerFor Novartis multimedia content, amuse appointment www.novartis.com/news/media-libraryFor questions about the armpit or appropriate registration, amuse acquaintance [email protected]
References National Heart, Lunch and Claret Institute. What Is Sickle Corpuscle Disease? Last updated: August 2, 2016. Accessible from: http://www.nhlbi.nih.gov/health/health-topics/topics/sca. Accessed on October 13, 2016.  Solomon LR. Assay and blockage of affliction due to vaso-occlusive crises in adults with sickle corpuscle disease: an educational void. Blood. 2008;111(3):997-1003. Published online October 16, 2007. Accessible from: http://www.ncbi.nlm.nih.gov/pubmed/17940207. Accessed October 13, 2016. The Mayo Clinic. Diseases and Conditions: Sickle Corpuscle Anemia. Mayo Clinic Staff. Last adapted June 2014. Accessible from http://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/basics/symptoms/con-20019348. Accessed October 13, 2016.
# # #
Novartis Media RelationsCentral media line: 41 61 324 2200E-mail: [email protected]
Novartis Broker RelationsCentral broker relations line: 41 61 324 7944E-mail: [email protected]
10 Brilliant Ways To Advertise Http Www Gidocs Net Clinic Information Patient Forms | Http Www Gidocs Net Clinic Information Patient Forms – http www gidocs net clinic information patient forms
| Encouraged in order to my personal website, in this particular moment I’ll provide you with with regards to http www gidocs net clinic information patient forms